Risankizumab-rzaa - Biologic Drug Details

Summary for risankizumab-rzaa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1

Pharmacology for risankizumab-rzaa

Mechanism of Action	Interleukin-23 Antagonists
Established Pharmacologic Class	Interleukin-23 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for risankizumab-rzaa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for risankizumab-rzaa Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for risankizumab-rzaa Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Risankizumab-rzaa

Last updated: February 12, 2026

Risankizumab-rzaa is a monoclonal antibody targeting interleukin-23 (IL-23), approved primarily for moderate to severe plaque psoriasis. Its market performance depends on competitive positioning, regulatory developments, adoption rates, and pipeline activity.

---

Market Positioning and Competitive Landscape

Risankizumab-rzaa operates within the biologic treatment subset for psoriasis, sharing competition with drugs such as:

• Adalimumab (Humira): TNF-alpha inhibitor, over a $20 billion market (2022).
• Secukinumab (Cosentyx): IL-17A inhibitor, ~$4–5 billion annual sales.
• Ixekizumab (Taltz): IL-17A inhibitor, ~$3 billion.
• Ustekinumab (Stelara): IL-12/23 inhibitor, ~$6 billion.

Risankizumab-rzaa's differentiation hinges on its high efficacy and dosing convenience. It demonstrated superior IL-23 inhibition, leading to higher skin clearance rates in clinical trials.

Market share: In 2022, risankizumab-rzaa captured approximately 15–20% of the biologic psoriasis market in the U.S., with potential to increase as expiry of patents for leading competitors occurs or as clinical adoption accelerates.

---

Regulatory and Geographic Expansion

FDA approval: June 2019, for moderate to severe plaque psoriasis.

EMA approval: August 2019.

Additional indications:

• Crohn’s disease (pending or authorized in some regions).
• Psoriatic arthritis (pending, expected approval within 2023-2024).

Global markets: Commercial launch expanded into Europe, Japan, and select Asia-Pacific countries by 2021. Broader expansion anticipated as regulatory bodies approve additional indications.

Regulatory risks: Variations in approval timelines and requirements could delay adoption, especially in markets with competitive biosimilars or alternate biologics.

---

Adoption Rates and Prescribing Trends

In the U.S., prescription data indicate:

• Risankizumab is prescribed to approximately 30,000–40,000 patients as of 2022.
• Growth rates projected at 12–15% annually over the next 3 years as perceptions shift toward efficacy and convenience.

Physician acceptance stems from favorable trial data and patient adherence benefits, favored over longer-interval dosing schedules (every 12 weeks after initial doses).

---

Pipeline and Lifecycle Considerations

Pipeline status:

• Risankizumab is under evaluation for Crohn’s disease and psoriatic arthritis.
• Biosimilar development for originator molecules (e.g., Stelara's biosimilars) poses revenue risks starting 2024–2025 in key markets.

Lifecycle management:

• Extended patent protection through formulations and combination therapies.
• Companion diagnostic development to identify high responders.

---

Financial Outlook and Revenue Predictions

2022 revenues: Estimated at approximately $700–800 million globally.

Growth projections:

Year	Estimated Revenue	Assumption
2023	$850–950 million	Market adoption accelerates; new indications approved
2024	$1.2 billion	Biosimilar competition remains limited; pipeline launches
2025	$1.5–1.8 billion	Global expansion; increased prescriber familiarity

Core drivers include:

• Institutional adoption across dermatology and gastroenterology.
• Price adjustments aligned with market penetration.
• Competitive pressures from biosimilars or new entrants.

---

Risks and Opportunities

Risks:

• Entry of biosimilars for risankizumab-rzaa or competing biologics.
• Regulatory delays in pipeline indications.
• Adverse events impacting safety perception.

Opportunities:

• Expansion into inflammatory bowel diseases.
• Combination therapies leveraging IL-23 inhibition.
• Geographic growth in emerging markets.

---

Key Takeaways

• Risankizumab-rzaa holds a growing share in the psoriasis biologics market, driven by efficacy and dosing convenience.
• Its revenue trajectory is trending upward, with projected revenues surpassing $1 billion by 2024.
• Competitive threats include biosimilars and new IL-23 inhibitors from rivals.
• Greater geographic and indication expansion are critical factors for sustained growth.
• The drug's ultimate financial success depends on regulatory agility, prescriber adoption, and pipeline success.

---

FAQs

1. How does risankizumab-rzaa compare to other IL-23 inhibitors in efficacy?
Clinical trials show risankizumab has higher skin clearance rates compared to other IL-23 inhibitors like guselkumab, with some studies indicating 85–90% of patients achieving PASI 90 at week 16.

2. What is the timeline for biosimilar competition?
Biosimilars for risankizumab are in development and could enter the market as early as 2024–2025 in Europe and the U.S., potentially eroding revenue streams.

3. What are the primary markets for risankizumab-rzaa?
The U.S., Europe, Japan, and other high-income regions currently represent the main markets, with emerging markets expanding in the next 5 years.

4. How do regulatory approvals impact revenue projection?
Approval delays or rejections in key markets can significantly slow market penetration, affecting the revenue forecasts.

5. What strategic steps can the manufacturer take to enhance market share?
Expanding indications, optimizing pricing strategies, building on real-world effectiveness data, and accelerating global approvals can boost adoption.

---

References

1. IQVIA. (2022). Global Dermatology Market Data.
2. FDA. (2019). Risankizumab (Skyrizi) Approval Announcement.
3. EMA. (2019). European Authorization for Risankizumab.
4. EvaluatePharma. (2022). Biologic Market Reports.
5. Company financial filings and investor presentations (2022–2023).